A Parallel Group, Phase III, Randomized, Observer Blind, Placebo Controlled, Multi Center, Multinational, Multi Arm Study to Demonstrate Non-inferiority of the Immune Response of a Low Dose Compared to the Standard Dose and to Evaluate the Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (OPAL)
Latest Information Update: 06 Feb 2026
At a glance
- Drugs RSVt-vaccine-Sanofi (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms OPAL
- Sponsors Sanofi Pasteur
Most Recent Events
- 03 Feb 2026 Status changed from active, no longer recruiting to discontinued.
- 14 Jan 2025 Status changed from not yet recruiting to active, no longer recruiting.
- 29 Nov 2024 New trial record